Free Trial

BioAge Labs (BIOA) 10K Form and Latest SEC Filings 2026

BioAge Labs logo
$17.56 -1.16 (-6.19%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest BioAge Labs SEC Filings & Recent Activity

BioAge Labs (NASDAQ:BIOA) has submitted 90+ documents to the U.S. Securities and Exchange Commission (SEC) since 2024. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in BioAge Labs's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
BioAge Labs, Inc. Reports Ownership Change on Apr. 24, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
BioAge Labs Files Current Report on May. 8, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
BioAge Labs Files Quarterly Report on May. 8, 2026

The 10-Q contains BioAge Labs's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

BioAge Labs SEC Filing History

Browse BioAge Labs' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 12:18 PM
BioAge Labs (1709941) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G/A
05/08/2026 8:10 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2026 8:05 AM
BioAge Labs (1709941) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/24/2026 3:19 PM
BioAge Labs (1709941) Issuer
GOLDSTEIN DOV A MD (1120478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:25 PM
BioAge Labs (1709941) Filer
Form ARS
04/21/2026 3:05 PM
BioAge Labs (1709941) Filer
Form DEF 14A
04/21/2026 3:06 PM
BioAge Labs (1709941) Filer
Form DEFA14A
04/03/2026 3:07 PM
BioAge Labs (1709941) Issuer
RUBIN PAUL D (1210905) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 9:53 AM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/24/2026 3:22 PM
BioAge Labs (1709941) Filer
Form S-3ASR
03/24/2026 8:10 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2026 8:15 AM
BioAge Labs (1709941) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/02/2026 9:17 AM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 3:34 PM
Barton Shane (1836297) Reporting
BioAge Labs (1709941) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:36 PM
BioAge Labs (1709941) Issuer
Fortney Kristen (2032751) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:38 PM
BioAge Labs (1709941) Issuer
GOLDSTEIN DOV A MD (1120478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 3:40 PM
BioAge Labs (1709941) Issuer
Morgen Eric (2036289) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 5:23 PM
ADAR1 Capital Management, LLC (1940272) Filed by
BioAge Labs (1709941) Subject
Form SCHEDULE 13G/A
02/17/2026 2:02 PM
BioAge Labs (1709941) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G/A
02/03/2026 3:23 PM
BioAge Labs (1709941) Issuer
GOLDSTEIN DOV A MD (1120478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 8:43 AM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 3:32 PM
BioAge Labs (1709941) Filer
Form 424B5
01/22/2026 3:34 PM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2026 3:01 PM
BioAge Labs (1709941) Filer
Form 424B5
01/20/2026 8:05 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2026 3:36 PM
BioAge Labs (1709941) Subject
Fortney Kristen (2032751) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2026 3:16 PM
BioAge Labs (1709941) Subject
GOLDSTEIN DOV A MD (1120478) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 8:10 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 11:56 AM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 3:21 PM
BioAge Labs (1709941) Issuer
RUBIN PAUL D (1210905) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 10:23 AM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/05/2025 5:20 PM
BioAge Labs (1709941) Issuer
RUBIN PAUL D (1210905) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 3:30 PM
BioAge Labs (1709941) Subject
RUBIN PAUL D (1210905) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/04/2025 8:05 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 3:50 PM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 3:40 PM
BioAge Labs (1709941) Filer
Form S-3/A
11/05/2025 3:41 PM
BioAge Labs (1709941) Filer
Form S-3/A
10/02/2025 3:35 PM
BioAge Labs (1709941) Filer
Form S-3
Registration statement under Securities Act of 1933  
08/14/2025 7:07 PM
ADAR1 Capital Management, LLC (1940272) Filed by
BioAge Labs (1709941) Subject
Form SCHEDULE 13G
08/14/2025 2:01 PM
BioAge Labs (1709941) Subject
Cormorant Asset Management, LP (1583977) Filed by
Form SCHEDULE 13G/A
08/06/2025 3:35 PM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
$30 stock to buy before Starlink goes public (WATCH NOW!) (Ad)

In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel

Click here to watch this short 3-minute video now.
06/09/2025 3:41 PM
BioAge Labs (1709941) Issuer
GARNIER JEAN PIERRE (1184175) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 3:42 PM
BioAge Labs (1709941) Issuer
Davidson Michael H. (1573785) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 3:44 PM
BioAge Labs (1709941) Issuer
ENRIGHT PATRICK G (1253886) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 3:46 PM
BioAge Labs (1709941) Issuer
HEALY JAMES (1245624) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 3:47 PM
BioAge Labs (1709941) Issuer
Hemrajani Rekha (1771213) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:00 AM
BioAge Labs (1709941) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

BioAge Labs SEC Filings - Frequently Asked Questions

BioAge Labs (BIOA) has submitted 90+ filings to the SEC since 2024. You can browse the complete history or filter by form type using the tools above.

BioAge Labs's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on BioAge Labs's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BIOA) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners